 Home > Active Pharmaceutical Ingredients > Antineoplastic Agents > Odanacatib for Sale > Wholesale Odanacatib MK0822 Powder CAS603139-19-1 Anti-Osteoporosis API Intermediate For Clinical Trial Research

Wholesale Odanacatib MK0822 Powder CAS603139-19-1 Anti-Osteoporosis API Intermediate For Clinical Trial Research buy - large image1

Wholesale Odanacatib MK0822 Powder CAS603139-19-1 Anti-Osteoporosis API Intermediate For Clinical Trial Research buy - image1

Wholesale Odanacatib MK0822 Powder CAS603139-19-1 Anti-Osteoporosis API Intermediate For Clinical Trial Research buy - image2

Wholesale Odanacatib MK0822 Powder CAS603139-19-1 Anti-Osteoporosis API Intermediate For Clinical Trial Research buy - image3

Wholesale Odanacatib MK0822 Powder CAS603139-19-1 Anti-Osteoporosis API Intermediate For Clinical Trial Research buy - image4

Wholesale Odanacatib MK0822 Powder CAS603139-19-1 Anti-Osteoporosis API Intermediate For Clinical Trial Research

Name: Wholesale Odanacatib MK0822 Powder CAS603139-19-1 Anti-Osteoporosis API Intermediate For Clinical Trial Research
Brand: HyperChem
SKU: pr2608052861
Price: 400 USD
Availability: InStock

TDS 24 Inquiries

Unit Price:

$400-500/G FOB

Get Latest Price 

CAS No.:

603139-19-1

Grade:

Pharmaceutical Grade

Content:

99.9%

Port:

Hangzhou

Brand:

HyperChem

Packaging:

1kg/bag, 5kg/bag, 25kg/Drum

Sample Available:

Yes

Price valid (until):

2028-05-31

Contact Supplier

 Chat Now

Hangzhou Hyper Chemicals Limited

Company Type:

Trader

Location:

China

Payment Terms:

TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Average Lead Time:

10 days

Qualification:

Main Products:

Pharmaceuticals,Peptide,Cosmetics,Nutritional Supplements

 Visit Store

Product Description
Seller Information
Inquiry History

Description

Name	Odanacatib
CAS number	603139-19-1
Synonym	Odanacatib (MK-0822) Cathepsin K Inhibitor Odanacatib (MK-0822) CAS 603139-19-1 Raw Powder Odanacatib (MK-0822) Anti-Osteoporosis API Intermediate Odanacatib (MK-0822) High Purity Lab Research Compound Odanacatib (MK-0822) Bone Metabolism Research Raw Material
Related APIs #	MK-0674, CAS 887781-62-6 Balicatib, CAS 354813-19-7 ONO-5334, CAS 868273-90-9 Relacatib (SB-462795), CAS 603139-12-4 L-006235, CAS 640684-07-5 MIV-711, CAS 1354694-42-6
Description	Odanacatib (MK-0822) Comprehensive Professional Introduction Odanacatib, coded MK-0822 with CAS registry number 603139-19-1, represents a well-characterized selective small-molecule cathepsin K inhibitor developed for skeletal disorder research and pharmaceutical intermediate development. This compound is widely adopted by pharmaceutical R&D laboratories, preclinical research institutions and bulk fine chemical manufacturers as a core research raw material targeting abnormal bone remodeling pathways, with distinct structural advantages, stable physicochemical traits and differentiated pharmacological profiles compared with non-selective bone turnover regulators. This article systematically elaborates its core product properties, pharmacological functions, underlying molecular mechanisms and in vitro & in vivo efficacy data, without referencing formulations, hazardous chemical APIs or controlled therapeutic substances. Fundamental Chemical & Physical Product Properties Odanacatib carries the molecular formula C ₂ ₅H ₂ ₇F ₄ N ₃ O ₃ S with a molecular weight of 525.56 g/mol, classified as an oral-oriented small-molecule amide derivative with a multi-ring aromatic backbone modified by trifluoromethyl and methylsulfonyl functional groups. Commercial-grade Odanacatib exists as off-white to pale beige crystalline powder under standard ambient storage conditions, featuring low hygroscopicity and excellent thermal stability under sealed, cool and dry storage. Its predicted density stands at 1.4 g/cm³, with a calculated boiling point of 681.6 °C under standard atmospheric pressure, a logP value of 2.92 and topological polar surface area of 107.44, granting moderate lipophilicity to support transmembrane absorption in mammalian cell models. Core Pharmacological Functions & Therapeutic Effects The primary functional positioning of Odanacatib centers on controlled suppression of excessive bone resorption, specifically developed for research into postmenopausal skeletal fragility, age-related low bone mineral density and other metabolic bone disorders driven by hyperactive osteoclast activity. Distinct from broad-spectrum antiresorptive intermediates, Odanacatib achieves balanced bone remodeling regulation: it robustly lowers bone breakdown biomarkers while preserving partial physiological bone formation capacity, a unique trait that reduces the risk of suppressed osteoblast activity commonly observed with alternative bone turnover modulators. In preclinical and phase three clinical research datasets, once-weekly oral administration of Odanacatib generates sustained reduction of circulating bone resorption markers. Serum C-telopeptide of type I collagen decreases by 60% to 70% relative to control cohorts, while urinary N-telopeptide/creatinine ratios drop by approximately 50% within seven days after standardized oral dosing regimens. Long-term continuous exposure drives steady elevation of lumbar spine and hip bone mineral density over multi-year observation cycles, with quantitative computed tomography confirming optimized trabecular microarchitecture and improved cortical bone strength in treated subjects. Large-scale clinical trial enrolling over 16,000 participants demonstrated measurable reduction in fragility fracture risks across spinal, hip and peripheral skeletal sites, with consistent tolerability profiles across multi-year treatment durations. Preclinical animal models with estrogen depletion display significant elevation of femoral neck and proximal femur bone density after sustained Odanacatib exposure, confirming translatable skeletal protective effects across mammalian species including rodents and non-human primates. Detailed Mechanism of Action Cathepsin K, a lysosomal cysteine protease highly enriched within mature osteoclasts, acts as the primary enzymatic mediator responsible for degrading type I collagen, the dominant organic structural component of mineralized bone matrix during physiological remodeling cycles. Under pathological conditions such as estrogen deficiency, osteoclast differentiation accelerates and intracellular cathepsin K expression surges, leading to unregulated breakdown of bone matrix, loss of bone mass and deterioration of skeletal mechanical integrity. Odanacatib operates as a reversible, highly selective neutral inhibitor that binds tightly to the active catalytic pocket of human cathepsin K with an IC50 value of 0.2 nM, while displaying minimal cross-reactivity against off-target cysteine proteases including cathepsin B, L and S, eliminating off-pathway enzymatic interference that compromises experimental accuracy in research assays. Upon oral absorption and systemic distribution, Odanacatib penetrates osteoclast cytoplasmic compartments and lysosomal vesicles, blocking the proteolytic cleavage activity of cathepsin K without suppressing osteoclast proliferation or differentiation itself. This targeted inhibition disrupts the breakdown of collagen fibrils within resorption lacunae, slowing the rate of bone matrix erosion while retaining intact osteoclast viability to sustain physiological coupling signals between bone-resorbing osteoclasts and bone-building osteoblasts. Unlike non-selective antiresorptive agents that halt both resorption and formation pathways simultaneously, Odanacatib-modulated osteoclasts secrete elevated concentrations of osteogenic coupling factors including sphingosine-1-phosphate, BMP-2 and IGF-1, shortening the reversal phase between bone resorption and new bone matrix deposition, which facilitates accelerated osteoblast recruitment to remodeled bone surfaces. Pharmacokinetic profiling further supports its long-acting research utility: the terminal elimination half-life reaches approximately 85 hours in human subjects, enabling low-frequency oral dosing schedules and stable sustained target engagement. Roughly 70% of absorbed Odanacatib undergoes hepatic metabolic clearance, with the remaining fraction excreted via biliary and urinary routes as unchanged parent compound, featuring low systemic clearance and predictable exposure-response correlations that simplify preclinical dosage modeling for laboratory study design. High-fat dietary co-administration moderately elevates systemic bioavailability, while low-fat meals produce mild exposure increases, providing standardized reference parameters for formulation and oral bioavailability research. Industrial & Research Application Value As a premium pharmaceutical intermediate, high-purity Odanacatib powder serves three core global demand segments: academic skeletal biology laboratories conducting bone remodeling pathway research, biotech enterprises advancing novel anti-osteoporosis candidate development, and analytical standard suppliers providing reference compounds for biomarker detection assay calibration. Its unmatched target selectivity and well-documented preclinical and clinical data render it a gold-standard positive control reagent for in vitro cathepsin K enzyme inhibition screening, ex vivo osteoclast culture testing and in vivo skeletal disease animal model validation. Global bulk buyers prioritize consistent HPLC purity, complete analytical certification and stable batch-to-batch uniformity, all standard deliverables for factory-supplied Odanacatib raw material without restricted handling limitations for non-clinical research usage.
Molecular Formula	C ₂₅ H ₂₇ F ₄ N ₃ O ₃ S
Molecular Weight	525.6 g/mol
Appearance	White or almost white powder
Quality Standard	Enterprise standard
Shipping Condition	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition	Dry, dark and at 0-28℃ for short term (days to weeks) or 8-20 ℃ for long term (months to years).
Shelf Life	>2 years if stored properly
Sample package	Double plastic bags inside, fiber drum outside, any quantity available.
Commercial package	Aluminium Tin, Fiber drum
Origin	China

Product Image

Shop USP Quality Standard API Finasteride Powder with CAS 98319-26-7-Detailed Image 2

Shop USP Quality Standard API Finasteride Powder with CAS 98319-26-7-Detailed Image 3

FAQ

Q1. What is the Hyper chem payment term?
T/T advance
LC at sight
DP at sight
Trade assurance
Money gram

Q2. What is Hyper chem shipment policy?
Our policy is to strive for the quickest shipment time possible, with ready stock sample shipment typically going out the same day that your order was placed. Your satisfaction is very important to us.
For non-ready stock, please contact the Hyper Chem sales team to negotiate.

Q3. What hyper chem will provide after shipment?
For sample orders:
After shipment is done, an timely email including:

Track details (Fedex /TNT/DHL/EMS Track number)

Package photo

COA, MSDS, etc

Dispatch date & Estimated arriving time

Shipping invoice

For commercial orders
A full set of shipment documents as well as package photos can be provided
in scan-copy and original, to help customers complete the customs clearance process.

Q4. What is Hyper Chem shipment term?

By Express
DHL  FedEx  TNT  EMS
Fast:5 days around
High cost, door to door service

By Air
Suitable for more than 50kg
Fast :3-7 days Hight cost, port to port, professional broker needed

By Sea
Suitable for more than 500kg
Slow:7-45 days, Low cost, port to port, professional broker needed
We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.

Q5. Does hyper chem provide a shipment return policy?
Yes, we have.
Return Policy: At Hyper chem, your satisfaction is guaranteed. If you are dissatisfied for any reason with a product, please send back the unused portion along with your packing slip and a brief note on why you were dissatisfied within 45 days of purchase for a full refund to:

Q6. What is hyper chem After-sales service
•Documents support: COA ,MSDS, MOA ,MS Report,HNMR Report,SDS,DMF
• Customer Support: Shipment clearance support, quality issue support
• Automated Customer Service: Our worldwide customers enjoy immediate 24/7 access to the HYPER CHEM support team from any location, at any time.

Company profile

Established in 2013, Hyper Chem has exclusive tie-ups with leading manufacturers, supplying raw materials produced in GMP and ISO 9002 certified facilities, and provides high-quality ingredients and raw materials to cater to the requirements of our diverse range of clients.

Among them, our key client industrial sectors around the global are:

Pharmaceuticals
Nutrition Ingredients/ Dietary supplements
Cosmetic Ingredients
Food Ingredients
Veterinary API
Agriculture fertilizer
Custom Synthesis lab supply

HyperChem provides to its wonderful and honorable clients comprehensive purchasing and distribution services which ensure that we are delivering the right generic, raw, or customized product, make sure that we are delivering it at the right time, ensure that it is delivered in the specified amount, and in the right kind of packaging to clients and customers of all types of industries irrespective of their size of operation.

ECHEMI Editorial Reference

Odanacatib (MK-0822) is a potent and selective inhibitor of cathepsin K, with an IC50 of 0.2 nM for human cathepsin K.
Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis. The drug made it to phase III trials before abandoned due to increased stroke.|Odanacatib is an inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K, which may result in a reduction in bone resorption, improvement of bone mineral density, and a reversal in osteoporotic changes. Cathepsin K, a tissue-specific cysteine protease that catalyzes degradation of bone matrix proteins such as collagen I/II, elastin, and osteonectin plays an important role in osteoclast function and bone resorption.

Research & Reference Note

Wholesale Odanacatib MK0822 Powder CAS603139-19-1 Anti-Osteoporosis API Intermediate For Clinical Trial Research is listed on ECHEMI for industrial / laboratory sourcing. This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

Authoritative sources

Disclaimer: This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

Reviewed by ECHEMI Scientific Review - Platform editorial review for research chemicals

Certificates

Basic Info

Product Name:

Odanacatib

Other Name:

Pentanamide,N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)[1,1′-biphenyl]-4-yl]ethyl]amino]-,(2S)-;(2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)[1,1′-biphenyl]-4-yl]ethyl]amino]pentanamide;Odanacatib;N1-[(1-Cyanocyclopropyl)-4-fluoro-N2-[(1S)-2,2,2-trifluoro-1-[4-methylsulfonyl]-1,1′-biphenyl-4-yl] ethyl]-L-leucinamide

CAS No.:

603139-19-1

Molecular Formula:

C25H27F4N3O3S

InChIKeys:

InChIKey=FWIVDMJALNEADT-SFTDATJTSA-N

Molecular Weight:

525.564

Exact Mass:

525.56

EC Number:

1533716-785-6

UNII:

N673F6W2VH

DSSTox ID:

DTXSID40209075

NCI Thesaurus Code:

C66981

Categories:

Antineoplastic Agents

Characteristics

PSA:

107

XLogP3:

4.1

Density:

1.4±0.1 g/cm3

Melting Point:

223-224 °C

Boiling Point:

681.6±55.0°C at 760 mmHg

Flash Point:

366.0±31.5 °C

Refractive Index:

1.563

See More Odanacatib Properties 

Hazard Identification

Classification of the substance or mixture

Specific target organ toxicity â repeated exposure, Category 1

GHS label elements, including precautionary statements

Precautionary statement(s)
Pictogram(s)
Signal word	Danger
Hazard statement(s)	H373 May cause damage to organs through prolonged or repeated exposure
Prevention	P260 Do not breathe dust/fume/gas/mist/vapours/spray. P264 Wash ... thoroughly after handling. P270 Do not eat, drink or smoke when using this product.
Response	P319 Get medical help if you feel unwell.
Storage	none
Disposal	P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

Other hazards which do not result in classification

no data available

Handling and Storage

Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

Conditions for safe storage, including any incompatibilities

Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

See More Odanacatib Safety Data Sheet 

Seller Information

Business Type:
Trader

Main Products:
Pharmaceuticals,Peptide,Cosmetics,Nutritional Supplements

Location:
Rm. 803, Tower 4, LOFT49 Creative City Pioneer Zone, No.88 Jiru Rd. Gongshu Dist., Hangzhou, 310015 ZJ, China

Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Average lead Time:
10 days

Total Annual Revenue:
$5 million-$10 million

Total Employees:
11-50

Year of Establishment:
2013

Company Certificates
- Certification Report by Bureau Veritas
About HyperChem

Established in 2013, Hyper Chem has exclusive tie-ups with leading manufacturers, supplying raw materials produced in GMP and ISO 9002 certified facilities, and provides high-quality ingredients and raw materials to meet the needs of a diverse range of pharmaceutical cosmetics ingredients and nootropic supplements companies worldwide.

Our Competitiveness

One-stop supply

Wide Range Of products including pharmaceutical, Cosmetic Ingredients and nootropic supplements

Among all the pharmaceuticals,

90% of them with GMP certificates,

85% of them with DMF files and

50% of them passed FDA approval,

30% get CEP certificate

20% are new R&D products.

Custom Repackaging Service

We can efficiently repackage your material into sample sizes, custom batch-specific sizes, or semi-bulk package sizes according to your specifications. And ensures the product is packaged in a quality-controlled environment and will maintain its integrity throughout every stage of the process.

Quality Control/Quality Assurance

HyperChem is committed to delivering on its promises of top-quality products with verified quality data.

All materials are vigorously inspected by the factory and/or outsourced analytical laboratories to ensure each and every lot meets or exceeds our reference standards.

Trade assurance service with 100% payment protection, It is best achieved by delivering products and services 100% right the first time, on time, every time.

Professional

Transparent Communication

Fast Reaction,

Professional Suggestion

Beyond Expectation.

We have exclusive partnerships with research and production facilities across the country and we offer varied pharmaceutical services in the most cost-efficient way. The production facilities are GMP, WHO-GMP, EU GMP and US FDA approved and are backed by strong regulatory support such as Dossier, DMF, Tech Pack and relevant Stability studies for regulatory filings.

Inquiry History

24 Inquiries

Country	Product	Purchase Quantity	Date Posted
United States	Odanacatinib	1 G	Sep 6, 2026
Germany	Odanacatib	3 G	Aug 1, 2026
United Kingdom	odanacatib	1 G	Sep 1, 2026
United Kingdom	Odanacatib	2 G	Aug 3, 2026
United States	odanacatib	20 G	Aug 2, 2026
Switzerland	Odanacatib	10 G	Jul 31, 2026
India	MK-0822	500 G	Jul 24, 2026
United Kingdom	Odanacatib	100 G	Sep 20, 2026
Romania	Odanacatib	9 G	Sep 14, 2026
United States	odanacatib	1 G	Sep 6, 2026
Germany	Odanacatib	1 G	Aug 11, 2026
Kazakstan	Odanacatib	1 G	Aug 7, 2026
United States	odanacatib	10 G	Jul 27, 2026
Ireland	Odanacatib	5 G	Jul 13, 2026
United States	Odanacatib	1 G	Jul 6, 2026
Denmark	Odanacatib	1 G	Sep 27, 2026
United States	Odanacatib	1 G	Sep 14, 2026
France	Odanacatib	750 MG	Sep 13, 2026
Canada	Odanacatib	1 G	Sep 8, 2026
United States	Odanacatib	3 G	Sep 7, 2026

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
Custom Chemical 98% HPLC MK-0822 MK0822 Raw Powder Odanacatib CAS 603139-19-1	Research Grade/99	$320-380/G FOB	Xi'an Horlden Bio-Tech Co., Ltd	Inquiry
Odanacatib, CAS 603139-19-1 purity 98% In stock with safety shipment	Chemical Grade/99	$10.3-11.33/G FOB	Wuhan Pnq Int Trade Co., Ltd	Inquiry
Odanacatib (MK-0822) 99% CAS 603139-19-1 China original factory best price Quality Assured	Pharma Grade/99	$49/G FOB	HNB Biotech	Inquiry
Odanacatib MK-0822 CAS 603139-19-1 Raw Powder Pharmaceutical Intermediate 98%	Industrial Grade/98	$40-50/G FOB	Shandong Guozhao Import and Export Co., Ltd.	Inquiry
Odanacatib Powder MK0822 CAS 603139-19-1 High purity 99% bulk raw	Pharmaceutical Grade/98	$1/G FOB	Hubei Meisang Trading Co.,Ltd	Inquiry

Wholesale Odanacatib MK0822 Powder CAS603139-19-1 Anti-Osteoporosis API Intermediate For Clinical Trial Research

Product Description

Seller Information